Phenotyping of COPD: Challenges and next steps

The Lancet Respiratory Medicine

Volumn 2, Issue 3, 2014, Pages 172-174

  Bourbeau, Jean ^a,b   Pinto, Lancelot M ^a   Benedetti, Andrea ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; FACTORIAL ANALYSIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MEDICAL DECISION MAKING; METHODOLOGY; NOTE; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYMPTOM;

FORCED EXPIRATORY VOLUME; HUMANS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84895799793     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70039-6     Document Type: Note

References (11)

1. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122.
2. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Resp Crit Care Med 2013, 187:347-365.
3. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Resp Crit Care Med 2010, 182:598-604.
4. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010, 36:531-539.
5. Burgel PR, Roche N, Paillasseur JL, et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J 2012, 40:495-496.
6. Cho MH, Washko GR, Hoffmann TJ, et al. Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 2010, 11:30.
7. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:728-735.
8. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011, 66:430-437.
9. Spinaci S, Bugiani M, Arossa W, Bucca C, Rolla G A multivariate analysis of the risk in chronic obstructive lung disease (COLD). J Chronic Dis 1985, 38:449-453.
10. Ringner M What is principal component analysis?. Nat Biotech 2008, 26:303-304.
11. Disantostefano RL, Li H, Rubin DB, Stempel DA Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open 2013, 3:e001838.